Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review

被引：40

作者：

Assi, Tarek ^{[1
]}

Kattan, Joseph ^{[1
]}

Rassy, Elie ^{[1
,2
]}

Nassereddine, Hussein ^{[1
]}

Farhat, Fadi ^{[1
]}

Honore, Charles ^{[2
]}

Le Cesne, Axel ^{[2
]}

Adam, Julien ^{[2
]}

Mir, Olivier ^{[2
]}

机构：

[1] St Joseph Univ, Dept Hematol Oncol, Fac Med, Beirut, Lebanon

[2] French Sarcoma Grp, Gustave Roussy Canc Campus, Villejuif, France

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 153卷

关键词：

Liposarcoma; Soft tissue sarcoma; CDK4; MDM2; Palbociclib; Abemaciclib; Ribociclib; SOFT-TISSUE SARCOMA; PHASE-II; 1ST-LINE TREATMENT; SYNOVIAL SARCOMA; INHIBITOR; CANCER; DOXORUBICIN; ABEMACICLIB; PALBOCICLIB; EFFICACY;

D O I：

10.1016/j.critrevonc.2020.103029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Well-differentiated/dedifferentiated (WD/DD) liposarcomas, the most common form of liposarcomas, constitute up to 20 % of all soft tissue sarcomas. Several oncogenes are thought to be involved in liposarcoma pathogenesis, mainly MDM2, CDK4 and HMGA2. While MDM2 inhibitors are now tested in clinical trials, a second actionable and promising target appears to be cyclin-dependent kinase 4 (CDK4), which is amplified in up to 90 % of well differentiated or dedifferentiated (WD/DD) liposarcoma. With the paucity of available therapeutic options, the inhibition of CDK4 represent a potential therapeutic option. In this paper, we review the role of CDK4/6 inhibitors in targeting the commonly identified CDK4 amplification in WD/DD liposarcoma, with an emphasis on the published and currently ongoing trials.

引用

下载

页数：6

共 50 条

[21] Design, synthesis, and biological evaluation of aminothiazoles as selective inhibitors of cyclin-dependent kinase 4 (CDK4).
Lovey, A
Depinto, W
Ding, QJ
Jiang, N
Kim, KJ
Yin, XF
Chu, XJ
Bartkovitz, D
Desai, B
Smith, M
Mullin, J
Mccomas, W
Graves, B
Lukacs, C
So, SS
Chen, YS
Xiang, D
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U132 - U132
[22] Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging
Graf, F.
Mosch, B.
Koehler, L.
Bergmann, R.
Wuest, F.
Pietzsch, J.
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2010, 10 (06) : 527 - 539
[23] Cyclin-dependent kinase (cdk) inhibitors/cdk4/cdk2 complexes in early stages of mouse mammary preneoplasia
Said, TK
Moraes, RCB
Singh, U
Kittrell, FS
Medina, D
CELL GROWTH & DIFFERENTIATION, 2001, 12 (06): : 285 - 295
[24] Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells
Jia, Bin
Choy, Edwin
Cote, Gregory
Harmon, David
Ye, Shunan
Kan, Quancheng
Mankin, Henry
Hornicek, Francis
Duan, Zhenfeng
CANCER LETTERS, 2014, 342 (01) : 104 - 112
[25] Postnatal Schwann cell proliferation but not myelination is strictly and uniquely dependent on cyclin-dependent kinase4 (cdk4)
Atanasoski, Suzana
Boentert, Matthias
De Ventura, Lukas
Pohl, Hartmut
Beier, Konstantin
Young, Peter
Barbacid, Mariano
Suter, Ueli
NEURON GLIA BIOLOGY, 2007, 2 : S141 - S141
[26] INHIBITION STUDIES OF TERPENE BASED NATURAL PRODUCTS WITH CYCLIN-DEPENDENT KINASE 4 (CDK4 MIMIC CDK2)
Ganatra, Sunil H.
Suchak, Amita S.
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2012, 3 (09): : 3196 - 3203
[27] Inhibition cyclin dependent kinase 4 (CDK4) activity by thiazolidinones
Pallela, Venkat R.
Natala, Srinivas R.
Cosenza, Stephen C.
Mallireddigari, Muralidhar R.
Pappathi, Nabissa
Akula, Balaiah
Billa, Vinaykumar
Reddy, E. Premkumar
Reddy, MV. Ramana
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
[28] Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
Kang, Jian
Sergio, C. Marcelo
Sutherland, Robert L.
Musgrove, Elizabeth A.
BMC CANCER, 2014, 14
[29] Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
Jian Kang
C Marcelo Sergio
Robert L Sutherland
Elizabeth A Musgrove
BMC Cancer, 14
[30] Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors
Chandarlapaty, Sarat
Razavi, Pedram
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) : 1148 - +

← 1 2 3 4 5 →